PL405125A1 - Cząsteczka miR172 pochodzenia roślinnego lub jej syntetyczny ekwiwalent, sposób zmniejszania proliferacji limfocytów B oraz zastosowanie cząsteczki miR172 - Google Patents

Cząsteczka miR172 pochodzenia roślinnego lub jej syntetyczny ekwiwalent, sposób zmniejszania proliferacji limfocytów B oraz zastosowanie cząsteczki miR172

Info

Publication number
PL405125A1
PL405125A1 PL405125A PL40512513A PL405125A1 PL 405125 A1 PL405125 A1 PL 405125A1 PL 405125 A PL405125 A PL 405125A PL 40512513 A PL40512513 A PL 40512513A PL 405125 A1 PL405125 A1 PL 405125A1
Authority
PL
Poland
Prior art keywords
particle
mir172
mir173
lymphocytes
synthetic equivalent
Prior art date
Application number
PL405125A
Other languages
English (en)
Other versions
PL226431B1 (pl
Inventor
Anna Łukasik
Piotr Zielenkiewicz
Zofia Szweykowska-Kulińska
Leszek Pączek
Original Assignee
Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Uniwersytet Im. Adama Mickiewicza W Poznaniu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biochemii I Biofizyki Polskiej Akademii Nauk, Uniwersytet Im. Adama Mickiewicza W Poznaniu filed Critical Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority to PL405125A priority Critical patent/PL226431B1/pl
Priority to LTEP14766010.4T priority patent/LT3035941T/lt
Priority to EP14766010.4A priority patent/EP3035941B1/en
Priority to PCT/PL2014/000092 priority patent/WO2015026249A1/en
Priority to PT14766010T priority patent/PT3035941T/pt
Priority to RS20181518A priority patent/RS58431B1/sr
Priority to ES14766010T priority patent/ES2702638T3/es
Priority to US14/913,650 priority patent/US20160272966A1/en
Priority to DK14766010.4T priority patent/DK3035941T3/en
Priority to SI201431012T priority patent/SI3035941T1/sl
Priority to HRP20182115TT priority patent/HRP20182115T1/hr
Priority to HUE14766010A priority patent/HUE041520T2/hu
Publication of PL405125A1 publication Critical patent/PL405125A1/pl
Publication of PL226431B1 publication Critical patent/PL226431B1/pl
Priority to CY20181101368T priority patent/CY1121427T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Wynalazki dotyczą cząsteczki miR172 pochodzenia roślinnego lub jej syntetycznego ekwiwalentu, sposobu zmniejszania proliferacji limfocytów B oraz zastosowania, cząsteczki miR172 wybranej spośród miR172a lub miR172b w leczeniu schorzeń związanych z reakcjami zapalnymi czy też z zaburzeniami prawidłowego funkcjonowania układu immunologicznego. Celem niniejszego wynalazku jest dostarczenie nowej metody terapeutycznej, opierającej się na cząsteczkach miRNA, które poprzez oddziaływanie z mRNA czynnika związanego z aktywnością naturalnej sfingomielinazy (FAN), zmniejszają odpowiedź zapalną organizmu w różnego rodzaju schorzeniach immunologicznych.
PL405125A 2013-08-23 2013-08-23 Cząsteczka miRNA do zastosowania do wytwarzania leku do zmniejszania reakcji zapalnej lub zapobiegania zwiększaniu się reakcji zapalnej organizmu PL226431B1 (pl)

Priority Applications (13)

Application Number Priority Date Filing Date Title
PL405125A PL226431B1 (pl) 2013-08-23 2013-08-23 Cząsteczka miRNA do zastosowania do wytwarzania leku do zmniejszania reakcji zapalnej lub zapobiegania zwiększaniu się reakcji zapalnej organizmu
US14/913,650 US20160272966A1 (en) 2013-08-23 2014-08-13 Method of using a miR172 Molecule for Decreasing Inflammation
DK14766010.4T DK3035941T3 (en) 2013-08-23 2014-08-13 USING A MIR172 MOLECULE TO REDUCE INFLAMMATION
PCT/PL2014/000092 WO2015026249A1 (en) 2013-08-23 2014-08-13 Use of a mir172 molecule for decreasing inflammation
PT14766010T PT3035941T (pt) 2013-08-23 2014-08-13 Utilização de uma molécula de mir172 para reduzir a inflamação
RS20181518A RS58431B1 (sr) 2013-08-23 2014-08-13 Primena mir172 molekula za smanjivanje upala
ES14766010T ES2702638T3 (es) 2013-08-23 2014-08-13 Uso de una molécula de MIR172 para reducir la inflamación
LTEP14766010.4T LT3035941T (lt) 2013-08-23 2014-08-13 Mir172 molekulės panaudojimas mažinant uždegimą
EP14766010.4A EP3035941B1 (en) 2013-08-23 2014-08-13 Use of a mir172 molecule for decreasing inflammation
SI201431012T SI3035941T1 (sl) 2013-08-23 2014-08-13 Uporaba molekule MIR172 za zmanjšanje vnetja
HRP20182115TT HRP20182115T1 (hr) 2013-08-23 2014-08-13 UPORABA MOLEKULE miR172 ZA SMANJENJE UPALE
HUE14766010A HUE041520T2 (hu) 2013-08-23 2014-08-13 MIR172 molekula alkalmazása gyulladás csökkentésére
CY20181101368T CY1121427T1 (el) 2013-08-23 2018-12-19 Χρηση ενος μοριου mir172 για τη μειωση της φλεγμονhς

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL405125A PL226431B1 (pl) 2013-08-23 2013-08-23 Cząsteczka miRNA do zastosowania do wytwarzania leku do zmniejszania reakcji zapalnej lub zapobiegania zwiększaniu się reakcji zapalnej organizmu

Publications (2)

Publication Number Publication Date
PL405125A1 true PL405125A1 (pl) 2015-03-02
PL226431B1 PL226431B1 (pl) 2017-07-31

Family

ID=51539311

Family Applications (1)

Application Number Title Priority Date Filing Date
PL405125A PL226431B1 (pl) 2013-08-23 2013-08-23 Cząsteczka miRNA do zastosowania do wytwarzania leku do zmniejszania reakcji zapalnej lub zapobiegania zwiększaniu się reakcji zapalnej organizmu

Country Status (13)

Country Link
US (1) US20160272966A1 (pl)
EP (1) EP3035941B1 (pl)
CY (1) CY1121427T1 (pl)
DK (1) DK3035941T3 (pl)
ES (1) ES2702638T3 (pl)
HR (1) HRP20182115T1 (pl)
HU (1) HUE041520T2 (pl)
LT (1) LT3035941T (pl)
PL (1) PL226431B1 (pl)
PT (1) PT3035941T (pl)
RS (1) RS58431B1 (pl)
SI (1) SI3035941T1 (pl)
WO (1) WO2015026249A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2856196T3 (es) * 2014-04-30 2021-09-27 Edmund Mach Fond Extracto de ARNp de planta o miARN de planta para uso como agente inmunosupresor
EP3216869B1 (en) 2016-03-09 2019-09-18 Colizzi, Vittorio Nutraceutical plant derived microrna elements for treatment of leukemia
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
AU2017378393B2 (en) 2016-12-14 2023-03-09 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4006768A1 (de) 1990-03-03 1991-09-05 Karatzanos Timoleon Entzuendungshemmendes und schmerzlinderndes mittel, insbesondere rheumamittel
JP2005517433A (ja) 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＴＮＦおよびＴＮＦレセプタースーパーファミリー遺伝子発現のＲＮＡ干渉媒介性阻害
JP4410451B2 (ja) 2002-03-15 2010-02-03 株式会社ファンケル 抗アレルギー、抗炎症用組成物
PL218992B1 (pl) 2002-07-19 2015-02-27 Abbott Biotech Ltd Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
AU2004280634A1 (en) * 2003-10-09 2005-04-21 E. I. Du Pont De Nemours And Company Gene silencing by using micro-RNA molecules
US8231872B2 (en) 2005-04-25 2012-07-31 The Trustees Of Dartmouth College Regulatory T cell mediator proteins and uses thereof
AU2012201409B2 (en) 2006-05-19 2014-06-12 Arrowhead Research Corporation RNAi-Mediated inhibition of tumor necrosis factor alpha-related conditions
EP2136846A4 (en) * 2007-03-26 2011-04-13 Crc For Asthma And Airways Ltd THERAPEUTIC OBJECTIVES AND MOLECULES
EP2152898A2 (en) * 2007-05-18 2010-02-17 Karolinska Institutet Innovations AB Microrna molecules associated with inflammatory skin disorders
WO2010118979A1 (en) * 2009-04-07 2010-10-21 Velin-Pharma A/S Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
US8962583B2 (en) * 2009-06-25 2015-02-24 The Brigham And Women's Hospital, Inc. Treatment of inflammatory diseases using miR-124
KR101090177B1 (ko) 2010-06-03 2011-12-06 건국대학교 산학협력단 인터류킨­32 길항적 ｒｎａ 앱타머
KR101263356B1 (ko) 2011-02-23 2013-05-16 정종문 항염증용 식품 조성물
WO2012153854A1 (ja) 2011-05-12 2012-11-15 学校法人立命館 サイトカイン・ケモカインモジュレーター
CN102887948B (zh) 2012-08-24 2014-06-11 复旦大学附属儿科医院 一种抗菌及免疫调节多肽类药物

Also Published As

Publication number Publication date
PT3035941T (pt) 2018-12-24
HRP20182115T1 (hr) 2019-03-22
WO2015026249A1 (en) 2015-02-26
LT3035941T (lt) 2019-02-11
EP3035941A1 (en) 2016-06-29
EP3035941B1 (en) 2018-10-03
SI3035941T1 (sl) 2019-04-30
US20160272966A1 (en) 2016-09-22
WO2015026249A8 (en) 2017-06-15
ES2702638T3 (es) 2019-03-04
DK3035941T3 (en) 2019-01-14
HUE041520T2 (hu) 2019-05-28
RS58431B1 (sr) 2019-04-30
PL226431B1 (pl) 2017-07-31
CY1121427T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
ECSP13012384A (es) Composición acuosa que contiene bromhexina
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112016010166A2 (pt) métodos para usar interleucina-10 para tratar doenças e distúrbios
BR112015016395A2 (pt) pirazóis 3-substituídos e uso como inibidores de dlk
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
TR201902516T4 (tr) Glukagon-glp-1-gıp üçlü agonist bileşikleri.
BR112015029970A2 (pt) inibidores de cinase
BR112014026703A2 (pt) inibidores de dna-pk
NZ716977A (en) Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases
MX2013008851A (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
JO3516B1 (ar) مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
BR112015029462A8 (pt) Inibidores de quinase
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso
WO2015026249A8 (en) Use of a mir172 molecule for decreasing inflammation
BR112015001859A2 (pt) tratamento de inflamação utilizando serelaxina
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
BR112014026158A2 (pt) métodos e composições para o tratamento de infecções virais